Review article: The pharmacology of rabeprazole

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 13, Issue 3, 1999, Pages 3-10

  Williams, M P ^a   Pounder, R E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; GASTRIN; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; STOMACH SECRETION INHIBITOR; UREASE;

ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; DOSE RESPONSE; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; MALE; NONHUMAN; NORMAL HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; STOMACH PH;

EID: 0032766682     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00019.x     Document Type: Review

References (49)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
2. Newton M. Bryan R, Burnham WR, Kamm MA, Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997; 40: 9-13.
3. Maton PN. Omeprazole. N Engl J Med 1991; 324; 965-75.
4. Hunt RH, pH and Hp gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993; 88: 481-3.
5. Cloud MI., Enas N, Humphries TJ, Bassion S, and the Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled doseresponse clinical trials in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993-1000.
6. Humphries TJ, Spera A, Breiter J, et al. Rabeprazole sodium once daily is superior to ranitidine 150 mg bid in the healing of active duodenal ulcer. Gastroenterology 1997; 112: A154 (Abstract).
7. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179-86.
8. Nakazawa S, Namiki M, Matsuo Y, et. al. An evaluation of the clinical usefulness of E3810 (rabeprazole sodium) for the treatment of gastric ulcers. Comparison with famotidine in a multi-center double-blind study. Clin Eval 1993; 21: 337-59.
9. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer-a European mullicentre study. Aliment Pharmacol Ther 1998; 12: 789-95.
10. Humphries T, Spera AC, Breiter J, et al. Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg qid in the healing of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology 1996; 110: A139 (Abstract).
11. Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 49-57.
12. Humphries TJ, Bassion S. Spanyers SA. Pilot studies on the effects of rabeprnzole sodium (E3810), amoxycillin, and placebo on the eradication of H. pylori. Am J Gastroenterol 1996; 91: 1914 (Abstract 123).
13. Stack WA, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 1998; 93: 1909-13.
14. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
15. Fujisaki H, Shibata H, Oketani K, et al. Inhibitions of acid secretion by E3810 and omeprazole and their reversal by glutathione. Biochem Pharmacol 1991; 42: 321-8.
16. +-ATPase. Biochem Pharmacol 1995; 49: 1729-34.
17. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22438-46.
18. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307-35.
19. Hunt RH, Cederberg C, Dent J, et al. Optimising acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995; 40 (Suppl. 1): 24S-49S.
20. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
21. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4: 25-33.
22. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 56-67.
23. Smout AJPM. Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent? Scand J Gastroenterol 1998; 33 (Suppl. 225): 32-5.
24. Martinek J, Blum AL, Stolte M, et al. Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 27-34.
25. +-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 1990; 39: 661-7.
26. +-ATPase is inhibited by E3810 (2-[{4-(3-methoxypropoxy)-3-methy[pyridin-2-yl}-methylsulfinyl]-1H- benzimidazole, sodium). FASEB J 1990; 4: A473 (Abstract).
27. Oketami K, Murakami M, Fujimoto M, Yamatsu I. The secretion of acid from isolated rabbit glands is inhibited by E3810 (2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}-methylsulfinyl]-1H- benzimidazole, sodium). FASEB J 1990; 4: A473 (Abstract).
28. Shibata H, Murakami M, Fujimoto M, Yamatsu I. Histamine stimulated gastric acid secretion is inhibited in gastric listula dogs treated with E3810 (2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}-methylsulfinyl]-1H- benzimidazole, sodium). FASEB J 1990; 4; A473 (Abstract).
29. Torniyama Y, Morii M, Takeguchi N. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 1994; 48: 2049-55.
30. Inoue M, Kimura S, Horikawa Y, et al. A study of the effects of the proton pump inhibitor E3810 (rabeprazole sodium) on gastric juice secretion. Basal and gastrin-stimulated gastric acid and pepsin secretion in healthy volunteers. Jpn Arch Intern Med 1994; 41: 143-50.
31. Lew EA, Barbuti RC, Kovacs TOG, Sytnic B, Humphries TJ, Walsh JH. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther 1998; 12: 667-72.
32. Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. A low dose of a new proton pump inhibitor LY-307640 (E3810) effectively inhibits acid secretion in humans. Gastroenterology 1996; 110(4): A161 (Abstract).
33. + activity and nocturnal acid secretion in healthy subjects. Gut 1996; 19 (Suppl. 3): A47 (Abstract).
34. Blanshard C, Millson C, Sercombe J, Pounder RE. The effects of rabepraxole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Gut 1996; 39 (Suppl. 3): A47 (Abstract).
35. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on the 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
36. Inoue M, Shirakawa T, Murakami Y, et al. Effect of a new proton pump inhibitor E3810 on intragastric pH in the patients with peptic ulcer. Gastroenterology 1991; 100 (5): A89 (Abstract).
37. Robinson M, Maton PN, Rodriguez S, Greenwood B, Humphries TJ. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 973-80.
38. Peterson WL. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 21-5.
39. Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823-37.
40. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 35: 490-6.
41. Weil J, Bell GD, Powell K, et al. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 1991; 5: 309-13.
42. Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: Unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993; 37: 769-74.
43. Lee A, Fox J, Hazell S. Pathogenicity of Helicobacter pylori: a perspective. Infect Immun 1993; 61: 1601-10.
44. McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology 1994; 107: 1573-8.
45. Mauch F, Bode G, Malfertheiner P, Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 1993; 88: 1801-2.
46. Hirai MH, Azuma T, Ito S, Kato T, Kohli Y. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 1995; 30: 461-4.
47. Fujiyama K, Fujioka T, Kodama R, Nasu M. Effect of E3810, a novel proton pump inhibitor, against Helicobacter pylori. Am J Gastroenterol 1994; 89: 1371 (Abstract).
48. Park J-B, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 1996; 19: 182-7.
49. Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995; 18: 1053-6.